Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Public ClinicalTrials.gov record NCT02462070. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Study identification
- NCT ID
- NCT02462070
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Enrollment
- 203 participants
Conditions and interventions
Conditions
Interventions
- IDP-118 Lotion Drug
- IDP-118 Vehicle Lotion Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 10, 2015
- Primary completion
- Nov 7, 2016
- Completion
- Nov 30, 2016
- Last update posted
- Aug 19, 2020
2015 – 2016
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valeant Site 3 | Mobile | Alabama | 36601 | — |
| Valeant Site 9 | Beverly Hills | California | 90210 | — |
| Valeant Site 12 | Encino | California | 91316 | — |
| Valeant Site 10 | San Diego | California | 92093 | — |
| Valeant Site 1 | Santa Rosa | California | 95403 | — |
| Valeant Site 16 | Denver | Colorado | 80123 | — |
| Valeant Site 2 | Tampa | Florida | 33601 | — |
| Valeant Site 7 | South Bend | Indiana | 46601 | — |
| Valeant Site 8 | Louisville | Kentucky | 40202 | — |
| Valeant Site 13 | Clinton Township | Michigan | 48036 | — |
| Valeant Site 14 | Rochester | New York | 14603 | — |
| Valeant Site 6 | Nashville | Tennessee | 37115 | — |
| Valeant Site 5 | Austin | Texas | 73344 | — |
| Valeant Site 4 | Houston | Texas | 77001 | — |
| Valeant Site 11 | Norfolk | Virginia | 23501 | — |
| Valeant Site 15 | Spokane | Washington | 99201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02462070, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02462070 live on ClinicalTrials.gov.